China Accepts Innovent's Sintilimab Combination for Melanoma Review

• China’s NMPA accepted Innovent Biologics’ application for sintilimab with Nolgileucel (GC101) for advanced melanoma.
• The proposed indication covers unresectable or metastatic melanoma progressing following at least two prior systemic therapies, including PD-1 antibody therapy.
• In a pivotal Phase II trial, median progression-free survival reached 4.3 months versus 1.6 months with chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260518PR_NEWS_USPR_____CN80607) on October 26, 2026, and is solely responsible for the information contained therein.